Bristol-Myers Squibb Co

Despite the medium-term uptrend, short-term momentum has weakened as price trades below the 9- and 20-day EMAs and pulls into the 50-day SMA. The 50-day SMA near 63.4 offers a high-quality support zone for a pullback-based entry in line with Growth at Reasonable Price principles. Execution should be deferred until the pullback is absorbed and price stabilizes around the 50-day SMA.

• ↑Q2 2026 revenue $7.3 B, up 14% YoY on robust growth portfolio
• ↑FDA accelerated approval of ZENBEXUS™ for multiple myeloma boosts pipeline
• ↓Analysts lower growth and revisions outlook; Milvexian study behind schedule